康泰医学(300869) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥99,175,164.46, a decrease of 73.10% compared to ¥368,699,882.77 in the same period last year[5] - Net profit attributable to shareholders was ¥4,351,935.11, down 97.44% from ¥170,052,052.02 year-on-year[5] - Basic earnings per share decreased to ¥0.0108, down 97.45% from ¥0.4232 in the same period last year[5] - Total operating revenue for Q1 2024 was ¥99,175,164.46, a decrease of 73.1% compared to ¥368,699,882.77 in the same period last year[20] - Net profit for Q1 2024 was ¥4,351,935.11, a significant decline from ¥170,052,052.02 in Q1 2023[21] - Earnings per share for Q1 2024 was ¥0.0108, compared to ¥0.4232 in the previous year[21] - The company reported a total comprehensive income of ¥4,216,671.58 for Q1 2024, down from ¥169,492,486.63 in Q1 2023[21] Cash Flow - The net cash flow from operating activities was -¥546,439.44, a decline of 100.54% compared to ¥101,516,355.63 in the previous year[5] - The net cash flow from operating activities for Q1 2024 was -546,439.44, compared to 101,516,355.63 in Q1 2023, indicating a significant decline[24] - Total cash inflow from investment activities was 1,254,098,774.06, while cash outflow was 973,982,712.86, resulting in a net cash flow of 280,116,061.20, compared to -159,393,812.47 in the previous year[25] - Cash inflow from financing activities totaled 143,160,301.37, while cash outflow was 142,278,214.92, leading to a net cash flow of 882,086.45, contrasting with -210,776,064.17 in Q1 2023[25] - The total cash and cash equivalents at the end of Q1 2024 amounted to 749,573,920.22, up from 467,223,246.73 at the beginning of the quarter[25] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥3,098,264,542.21, a decrease of 3.54% from ¥3,211,946,652.17 at the end of the previous year[5] - Total current assets decreased from CNY 2,482,164,235.52 to CNY 2,150,686,350.48, a reduction of approximately 13.36%[17] - Total assets decreased from CNY 3,211,946,652.17 to CNY 3,098,264,542.21, a decrease of approximately 3.52%[18] - Total liabilities decreased to ¥1,049,248,899.15 from ¥1,167,149,962.89 year-over-year, reflecting a reduction of 10.1%[20] - Total equity increased slightly to ¥2,049,015,643.06 from ¥2,044,796,689.28, showing a growth of 0.2%[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 37,793[12] - The largest shareholder, Hu Kun, holds 46.84% of shares, totaling 188,189,252 shares[12] Operating Costs and Expenses - The company experienced a 62.06% reduction in operating costs, which amounted to ¥50,192,307.62 compared to ¥132,298,048.27 in the previous year[9] - Total operating costs for Q1 2024 were ¥102,176,199.13, down 48.2% from ¥197,193,260.98 year-over-year[20] - Research and development expenses for Q1 2024 were ¥27,140,047.87, up 8.6% from ¥25,005,015.83 in the previous year[20] - The company paid 42,581,872.43 in employee compensation, a decrease from 59,520,945.56 in the same quarter last year[24] Investment Income - The company reported a significant decrease in investment income, which fell by 71.86% to ¥7,695,776.25 from ¥27,350,274.44 year-on-year[9] - Cash received from investment income was 63,948,774.06, an increase from 26,683,525.05 in Q1 2023[24] Other Financial Metrics - The weighted average return on equity was 0.21%, down 8.24% from 8.45% in the same period last year[5] - The financial expenses for Q1 2024 showed a significant improvement, with a net income of -¥4,926,415.19 compared to -¥15,783,191.97 in the same period last year[20] - The company maintained a stable capital reserve of ¥345,145,796.40, reflecting consistent financial management[20] - The impact of exchange rate changes on cash and cash equivalents was 1,898,965.28, compared to 8,989,326.22 in Q1 2023[25] Miscellaneous - The company has not reported any changes in the number of preferred shareholders or any significant events during the reporting period[15] - The company has not indicated any new product developments or market expansion strategies in the current report[16] - Other receivables increased from CNY 7,093,404.07 to CNY 19,590,340.71, an increase of approximately 176.66%[17] - Short-term borrowings decreased from CNY 347,000,000.00 to CNY 237,000,000.00, a reduction of approximately 31.83%[18] - Accounts payable decreased from CNY 17,787,231.43 to CNY 13,996,438.68, a decrease of approximately 21.00%[18]